Valuation : DMS

Market Cap 26.3M 30.64M 24.63M 22.55M 42.48M 2.93B 42.6M 292M 114M 1.48B 115M 113M 4.88B P/E 2026 *
33.8x
P/E 2027 * 10.2x
Enterprise Value 41.7M 48.58M 39.04M 35.75M 67.35M 4.64B 67.54M 462M 181M 2.34B 182M 178M 7.74B EV / Sales 2026 *
0.73x
EV / Sales 2027 * 0.52x
Free-Float
69.9%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 53 2022-07-17
Director of Finance/CFO - 2021-12-31
Chief Tech/Sci/R&D Officer - 2018-12-31
Director TitleAgeSince
Chairman 53 2022-07-17
Director/Board Member 52 2025-06-15
Director/Board Member - 2023-07-23
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 30.65M
+1.30%-2.20%-21.41%+2.27% 12.86B
-0.14%-3.28%+20.78%+10.23% 4.51B
-0.21%-6.01%-44.16%-55.99% 1.23B
+2.96%-1.50%-37.93%-35.37% 1.16B
-0.60%+0.37%+17.81%+86.54% 1.12B
+3.30%-6.69%-41.06% - 1.05B
-0.32%-6.73%+40.23%+122.08% 525M
+3.87%+2.34%+52.73% - 291M
-2.22%-9.18%-66.78%+292.33% 246M
Average +0.79%-2.73%-8.87%+60.30% 2.55B
Weighted average by Cap. +0.98%-1.50%-12.31%+9.16%

Financials

2026 *2027 *
Net sales 56.8M 66.17M 53.18M 48.69M 91.73M 6.32B 91.99M 630M 246M 3.19B 248M 243M 10.54B 65.9M 76.77M 61.7M 56.49M 106M 7.33B 107M 731M 286M 3.7B 288M 282M 12.23B
Net income 800K 932K 749K 686K 1.29M 89.01M 1.3M 8.87M 3.47M 44.86M 3.5M 3.42M 148M 2.6M 3.03M 2.43M 2.23M 4.2M 289M 4.21M 28.82M 11.27M 146M 11.37M 11.13M 483M
Net Debt 15.4M 17.94M 14.42M 13.2M 24.87M 1.71B 24.94M 171M 66.74M 864M 67.36M 65.9M 2.86B 8M 9.32M 7.49M 6.86M 12.92M 890M 12.96M 88.69M 34.67M 449M 34.99M 34.23M 1.48B
Logo DMS
Diagnostic Medical Systems (DMS) is France's leader in the development, design, and production of imaging systems for digital and conventional radiology and osteodensitometry. The group's activity is organized around two sectors: - radiology equipment and osteodensitometers sales: mobile radiology units, floating table tops, operating room mobile amplifiers, ultrasound osteodensitometers (designed to chart the bone micro-architecture) and X ray osteodensitometers (designed to measure bone density), etc. The group also proposes devices distribution and maintenance activities; - development of biotechnology solutions: in the fields of arthrosis treatment and regenerative medicine. Products and services are marketed primarily by exclusive retailers. Net sales (not including sold divisions) are distributed geographically as follows: Europe (49.6%), North and South America (17%), Asia (7.5%), Middle East (7.5%), Africa (3.1%), Oceania (1%) and other (14.3%).
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-